Temocillin (BRL 17421) is a beta-lactam antibiotic, which is the 6-alpha-methoxy derivative of ticarcillin (see Chapter 9, Carbenicillin, carindacillin, carfecillin and ticarcillin). It has activity against aerobic Gram-negative bacteria except for Pseudomonas aeruginosa and Acinetobacter spp. Temocillin is stable against most types of beta-lactamases, including extended-spectrum and AmpC beta-lactamases (Solocombe et al., 1981). Temocillin is available in Belgium (Negaban), Luxembourg, and the UK as a parenteral antibiotic for the treatment of Gram-negative infections. Both the European Medicines Agency (EMEA) and the US Food and Drug Administration (FDA) have given temocillin orphan drug status for the treatment of infections caused by Burkholderia cepacia in patients with cystic fibrosis.
|Original language||English (US)|
|Title of host publication||Kucers the Use of Antibiotics|
|Subtitle of host publication||A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition|
|Number of pages||7|
|State||Published - Jan 1 2017|
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics(all)